The OTC market has always been an attractive destination for investors seeking to capitalize on the potential of small-cap stocks. With many stocks trading below $0.5, the market provides ample opportunities for investors looking for high-risk, high-reward momentum plays. Yesterday, several such stocks witnessed positive gains, and the question now is whether they can sustain that momentum. In this article, we will examine some potential momentum plays on the OTC market and analyze their prospects for the near future.

Epazz Inc. (OTC: EPAZ), a provider of drone technology, blockchain mobile apps, and cloud-based business software solutions, had a successful day on Thursday, finishing up 5.45%. ZenaDrone Inc., an EPAZ spinoff, has been focusing its attention on the development of its flagship drone, the ZenaDrone 1000.

ZenaDrone is positioned as one of the beneficiaries of the overall growth trend in the drone market. The Zenadrone 1000 is equipped with machine learning systems, AI technology, and multispectral sensors, making it suitable for use in various industries such as military, agriculture, and oil and gas. Additionally, the drone's ability to generate 3D interactive environment maps from the data collected by its cameras makes it highly versatile across different sectors.

Most recently, EPAZ announced that ZenaDrone Inc. is expanding its facilities in Dubai, UAE, to increase production of the ZenaDrone 1000. The expansion is needed to meet the requirements of several pilot program agreements that involve the extended use of ZenaDrone 1000 by customers.

Additionally, ZenaDrone has multiple drone demonstrations scheduled, which requires the need for more drones. Last year, ZenaDrone produced 10 ZenaDrone 1000; this year, the goal is to increase production to over 20 drones per month, with the capacity to produce 40 drones in the same facility. This expansion and increased production capacity will allow ZenaDrone to meet its obligations and increase its presence in the drone market.

CEO Shaun Passley, Ph.D., said, "We are encouraged by the level of interest we have received and, based on the pilot program agreements and the number of scheduled demonstrations, it is time to expand to double the size of our production facility."

The U.S. Air Force has expressed interest in using ZenaDrone 1000 for drone cargo delivery, which includes blood transport, and has invited ZenaDrone to conduct tests under battlefield conditions at an overseas base. ZenaDrone is also qualified to submit a Phase II SBIR grant for external funding of its cargo delivery solution, with grants generally up to $1.2 million for a two-year period.

Investors looking for exposure to the promising military drone market could consider Epazz Inc. (OTC: EPAZ) as a potentially attractive penny stock, given the potential for significant revenue growth from its flagship ZenaDrone product and the expanding demand for military drones in the US.

GBT Technologies Inc. (OTC: GTCH) is a development-stage company that specializes in creating technology for the Internet of Things (IoT), artificial intelligence (AI), and mobile technology platforms. Their experienced team is working on building an intellectual property portfolio that includes several patents.

GTCH's goal is to license this technology and intellectual property to other companies that work in hardware and software. Once their products are ready, they plan to offer a range of products that include smart microchips, AI, encryption, blockchain, IC design, mobile security applications, and database management protocols.

GTCH made a 37.50% jump in price on Thursday, following a press release titled, "GBT's intelligent, human vitals qTerm device patent received an issue notification."

The update detailed that the company has received notice that it will be granted a US patent on May 2, 2023, for its innovative human vitals device, which uses machine learning to analyze data.

The qTerm device is an intelligent, electronic health device that can measure body temperature, blood oxygen level, and heart rate with just a touch of a finger. This cutting-edge technology has been in development since 2020, and after rigorous testing and debugging, GBT successfully completed a fully working prototype in 2022, which included a participant study.

With this new patent, GBT is set to make a big impact in the healthcare industry and is sure to attract attention from investors looking to get in on the ground floor of this exciting new technology.

Therapeutic Solutions International, Inc. (OTC: TSOI) is focused on immune modulation for the treatment of several specific diseases. Wednesday and Thursday saw TSOI making considerable gains, finishing up 7.69% on Thursday

On April 20, TSOI announced that they have filed a Phase III clinical trial application with the FDA for its JadiCell adult stem cells in the treatment of acute respiratory distress syndrome (ARDS), based on their existing data and experiences in treating COVID-19-associated ARDS. ARDS affects around 190,000 Americans annually and is expected to reach a $19.5 billion market by 2029.

The decision to accelerate the development of the ARDS programs came in part from a published decision upholding the validity of Patent No. 9,803,176 B2, which covers the composition of matter of JadiCells exclusively licensed to TSOI for lung and brain indications. JadiCells have previously been shown to be 100% effective in COVID-19-induced ARDS patients under 85 years of age.

"The company has stayed a steady course in accomplishing its milestones of in-licensing an advanced cell therapeutic product, filing additional patents surrounding it, demonstrating in animal models and various clinical situations benefits of the product, and now taking the next step in product development by filing for entry into the ARDS patient population, which presents a significantly greater market than COVID-19-induced ARDS", said Dr. James Veltmeyer, Principle Investigator of the Study.

"We are happy to report the decision of our medical advisors to support entry of our adult stem cell-based product into the greater patient population of ARDS", said Timothy Dixon, President and CEO of the Company. "We have numerous physicians eager to join the new trial, including ones who have previously witnessed significant patient improvement in previous clinical uses of our cells."

This news could make TSOI a potential investment opportunity in the growing field of respiratory distress treatments.

Solar Integrated Roofing Corp. (OTC: SIRC) is a company that offers a range of services, including solar power, roofing, and EV charging systems. They focus on serving both commercial and residential properties in North America. SIRC finished up 5.45% on Thursday.

Thursday, SIRC announced that it has reached an agreement with Granite Global Value Investments LTD, one of its noteholders, to eliminate a $14 million promissory note issued by the company in June 2022.

In exchange for canceling the debt, Granite will receive 4,000,000 shares of common stock. This is a significant achievement in the company's ongoing efforts to reduce its debt and focus on growth, according to David Massey, the CEO of SIRC. The company believes that the agreement will provide more flexibility for the company to pursue strategic transactions or potentially list on a major stock exchange while also prioritizing operational execution to maximize value for shareholders.

Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Epazz Inc. to assist in the production and distribution of content. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

CONTACT: CapitalGainsReport

Mark McKelvie

Editor

Markrmckelvie@gmail.com

585-301-7700

.

(C) 2023 M2 COMMUNICATIONS, source M2 PressWIRE